Join us to stop malaria!

A Strategic Initiative to End Malaria Globally

Partner with Landcent to help eliminate one of the world’s deadliest—yet most preventable—diseases. Your support enables the development and delivery of impactful health solutions that target malaria at its source and save lives.

Landcent Europe, headquartered in the Netherlands with operations in Africa and Asia, accelerates the fight against diseases of poverty, starting with malaria.

“Malaria is Not Just a Health Crisis—It’s a Human Rights Issue” – Justin Hays, Vice President Landcent

Why malaria?
Its disproportionate impact on the poorest, those least able to afford preventative measures and medical treatment, makes eliminating malaria a human rights priority.

In 2023, malaria caused close to 600,000 deaths across 83 countries, with 94% of cases and 95% of deaths occurring in Africa. Most of those (76%!) who died were children under five. This is a preventable tragedy. Landcent focuses where the need is greatest—across the African continent—developing and delivering impactful health solutions like bed nets and antimalarials to stop malaria at its source.

Closing the Gap
Malaria prevention is falling behind due to lack of product innovation and the rise of insecticidal resistance. Landcent’s strategy is to disrupt the status quo through breakthrough improvements to current prevention tools—making them more effective, scalable, and sustainable. Landcent is also discovering and developing new active compounds to tackle resistance while protecting biodiversity—a cutting-edge initiative partially funded by the Gates Foundation.

“Widespread and increasing insecticide resistance poses a threat to effective malaria vector control. Failure to mitigate and manage insecticide resistance is likely to result in an increased burden of disease.” – World Health Organization

Impact  
By 2030, Landcent’s products, including Insecticide-Treated Nets (ITNs), Spatial Emanators (SEs) and Antimalarial pills would protect 200 million people across Sub-Saharan Africa, from malaria. Landcent’s Active Ingredient Discovery Platform will yield a new suite of sustainable compounds to control and contribute towards malaria elimination in the longer term.

Landcent’s Triple A Strategy—Products in Africa, for Africa, by Africans—strengthens healthcare across the continent by focusing on local production, tailored solutions, and the empowerment of regional expertise and industries. The establishment of Landcent’s office in Accra, Ghana, marks a key step toward expanding access to local markets and manufacturing capacity.

Funding 
Landcent is seeking a final $1M equity investment to complete our Track 1 funding round. With $1.5M already secured from early strategic investors, this last catalytic capital will unlock a $5M crowdfunding campaign—term sheet signed and ready to launch.

Your investment will help accelerate our growth and scale life-saving health innovations where they’re needed most.

Through MissionInvest USA, Landcent has partnered with Impact Foundation to enable investments of philanthropic capital using a straight-forward and transparent process:
1. Transfer of philanthropic funds to Impact Foundation.
2. Impact Foundation invests philanthropic capital into Landcent Europe as an equity investment on behalf of the donor.
3. Assuming the shares are sold in a few years, the funds will return to the Impact Foundation and can be reinvested in another project, aligned with the original donor’s preferences. Any eventual profit will also remain within the foundation. Through this model, your donation becomes recurring.

Over the past year, MissionInvest Netherlands has successfully raised over $8M in impact investment capital for Landcent’s short-term projects to combat malaria.

Malaria being one of the neglected disease areas, MissionInvest aims to raise $1.0M to positively impact the lives of people suffering due to the burden of malaria. Join along to achieve this remarkable goal!